Browsed by
Tag: biotechnology

UNITY Biotechnology Raises $116M for Senescent Cell Clearance Development – Article by Reason

UNITY Biotechnology Raises $116M for Senescent Cell Clearance Development – Article by Reason

The New Renaissance HatReason
******************************

The whispers of late have had it that UNITY Biotechnology was out raising a large round of venture funding, and their latest press release shows that this was indeed the case. The company, as you might recall, is arguably the more mainstream of the current batch of startups targeting the clearance of senescent cells as a rejuvenation therapy. The others include Oisin Biotechnologies, SIWA Therapeutics, and Everon Biosciences, all with different technical approaches to the challenge. UNITY Biotechnology is characterized by a set of high profile relationships with noted laboratories, venture groups, and big names in the field, and, based on the deals they are doing, appear to be focused on building a fairly standard drug development pipeline: repurposing of apoptosis-inducing drug candidates from the cancer research community to clear senescent cells, something that is being demonstrated with various drug classes by a range of research groups of late. Senescent cells are primed to apoptosis, so a nudge in that direction provided to all cells in the body will have little to no effect on normal cells, but tip a fair proportion of senescent cells into self-destruction. Thus the UNITY Biotechnology principals might be said to be following the standard playbook to build the profile of a hot new drug company chasing a hot new opportunity, and clearly they are doing it fairly well so far.

UNITY Biotechnology Announces $116 Million Series B Financing

Quote:

UNITY Biotechnology, Inc. (“UNITY”), a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing. The UNITY Series B financing ranks among the largest private financings in biotech history and features new investments from longtime life science investors ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, and Venrock. Other investors include Bezos Expeditions (the investment vehicle of Jeff Bezos) and existing investors WuXi PharmaTech and Mayo Clinic Ventures. Proceeds from this financing will be used to expand ongoing research programs in cellular senescence and advance the first preclinical programs into human trials.

The financing announcement follows the publication of research that further demonstrates the central role of senescent cells in disease. The paper, written by UNITY co-founders Judith Campisi and Jan van Deursen and published today, describes the central role of senescent cells in atherosclerotic disease and demonstrates that the selective elimination of senescent cells holds the promise of treating atherosclerosis in humans. In animal models of both early and late disease, the authors show that selective elimination of senescent cells inhibits the growth of atherosclerotic plaque, reduces inflammation, and alters the structural characteristics of plaque such that higher-risk “unstable” lesions take on the structural features of lower-risk “stable” lesions. “This newly published work adds to the growing body of evidence supporting the role of cellular senescence in aging and demonstrates that the selective elimination of senescent cells is a promising therapeutic paradigm to treat diseases of aging and extend healthspan. We believe that we have line of sight to slow, halt, or even reverse numerous diseases of aging, and we look forward to starting clinical trials with our first drug candidates in the near future.”

So this, I think, bodes very well for the next few years of rejuvenation research. It indicates that at least some of the biotechnology venture community understands the likely true size of the market for rejuvenation therapies, meaning every human being much over the age of 30. It also demonstrates that there is a lot of for-profit money out there for people with credible paths to therapies to treat the causes of aging. It remains frustrating, of course, that it is very challenging to raise sufficient non-profit funds to push existing research in progress to the point at which companies can launch. This is a problem throughout the medical research and development community, but it is especially pronrounced when it comes to aging. The SENS view of damage repair, which has long incorporated senescent cell clearance, is an even tinier and harder sell within the aging research portfolio – but one has to hope that funding events like this will go some way to turn that around.

From the perspective of being an investor in Oisin Biotechnologies, I have to say that this large and very visible flag planted out there by the UNITY team is very welcome. The Oisin team should be able to write their own ticket for their next round of fundraising, given that the gene therapy technology they are working on has every appearance of being a superior option in comparison to the use of apoptosis-inducing drugs: more powerful, more configurable, and more adaptable. When you are competing in a new marketplace, there is no such thing as too much validation. The existence of well-regarded, well-funded competitors is just about the best sort of validation possible. Well-funded competitors who put out peer-reviewed studies on a regular basis to show that the high-level approach you and they are both taking works really well is just icing on the cake. Everyone should have it so easy. So let the games commence! Competition always drives faster progress. Whether or not I had skin in this game, it would still be exciting news. The development of rejuvenation therapies is a game in which we all win together, when new treatments come to the clinic, or we all lose together, because that doesn’t happen fast enough. We can and should all of us be cheering on all of the competitors in this race. The quality and availability of the outcome is all that really matters in the long term. Money comes and goes, but life and health is something to be taken much more seriously.

Now with all of that said, one interesting item to ponder in connection to this round of funding for UNITY is the degree to which it reflects the prospects for cancer therapies rather than the prospects for rejuvenation in the eyes of the funding organizations. In other words, am I being overly optimistic in reading this as a greater understanding of the potential for rejuvenation research in the eyes of the venture community? It might be the case that the portions of the venture community involved here understand the market for working cancer drugs pretty well, and consider that worth investing in, with the possibility of human rejuvenation as an added bonus, but not one that is valued appropriately in their minds. Consider that UNITY Biotechnology has partnered with a noted cancer therapeutics company, and that the use of drugs to inducing apoptosis is a fairly well established approach to building cancer treatments. That is in fact why there even exists a range of apoptosis-inducing drugs and drug candidates for those interested in building senescent cell clearance therapies to pick through. Further, the presence of large numbers of senescent cells does in fact drive cancer, and modulating their effects (or removing them) to temper cancer progress is a topic under exploration in the cancer research community. So a wager on a new vision, or a wager on the present market? It is something to think about.

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
***
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.
An Interview with Kelsey Moody of Ichor Therapeutics, Bringing a SENS Therapy for Macular Degeneration to the Clinic – Article by Reason

An Interview with Kelsey Moody of Ichor Therapeutics, Bringing a SENS Therapy for Macular Degeneration to the Clinic – Article by Reason

The New Renaissance HatReason
******************************

As I mentioned last week, earlier this year Fight Aging! invested a modest amount in the Ichor Therapeutics initiative to develop a treatment for macular degeneration, joining a number of other amateur and professional investors in helping to get this venture started. The approach taken here is based on the results of research carried out at the Methuselah Foundation and SENS Research Foundation over much of the past decade, funded by philanthropists and the support of our community of longevity science enthusiasts. This is how we succeed in building the future: medical science in the laboratory leads to medical development in startup companies, each new stage bringing treatments capable of repairing specific forms of age-related molecular damage that much closer to the clinic.

Ichor Therapeutics is one of a growing number of success stories to emerge from the SENS rejuvenation research community. Young scientists, advocates, and donors involved in earlier projects – years ago now – have gone on to build their own ventures, while retaining an interest in stepping up to do something meaningful to help bring an end to aging. Back in 2010, Kelsey Moody worked on the LysoSENS project to find ways to break down damaging metabolic waste in old tissues; fast-forward six years, and he is the now the CEO of a successful small biotechnology company with a great team, taking that very same technology and putting it to good use. I recently had the chance to ask Kelsey a few questions about the future of SENS rejuvenation research, as well as how the Ichor scientists intend to construct a new class of therapy for macular degeneration, one based on removing one of the root causes of the condition.

Quote:

Who are the people behind Ichor Therapeutics? How did you meet and decide that this was the thing to do? Why macular degeneration as a target?

People have always been the focus of Ichor. Since day one we have worked to create a positive environment that cultivates a product-oriented research focus and emphasizes autonomy and personal accountability for work. As a result, ambitious self-starters tend to find their way to Ichor and remain here. However, we recognized early on that just filling a lab with a bunch of blue-eyed bushy tailed young up-and-comers is not sufficient to develop a robust, mature, translational pipeline. We have augmented our team with a number of critical staff members who are seasoned pharma operators, including our Quality Assurance Director and General Counsel.

Age-related macular degeneration (AMD) was chosen as a target because we believe it is the closest SENS therapy to the clinic. While we obviously have an interest in providing cures for the patients suffering from AMD and are attracted to the large market opportunities such a treatment could bring, our broader interest is in validating the entire SENS paradigm. We believe that Aubrey de Grey continues to receive excessive criticism because nothing spun out of SENS has ever made it into a legitimate pre-clinical pipeline, much less to the bedside. However, this does not mean he is wrong. Our goal is to be the first group to bring a SENS inspired therapy into the clinic and in doing so, silence critics and generate new energy and capital for this cause.

I understand there’s a lengthy origin story for the approach you are taking to treat AMD; it’d be great to hear some of it.

Our approach to treating AMD is based on the hypothesis that cellular junk that accumulates over the lifespan significantly contributes to the onset and progression of AMD. Our goal is to periodically reduce the burden of the junk so it never accumulates to levels sufficient to induce pathology. The strategy to accomplish this calls for the identification of enzymes that can break down the junk in a physiological setting, and the engineering of these enzymes such that they can break down the target in the correct organelle of the correct cell without appreciable collateral damage to healthy cells or tissue.

Methuselah Foundation and SENS Research Foundation did excellent work in establishing this program nearly a decade ago. They successfully identified a number of candidate enzymes that could break down the molecular junk, but reported that the targeting systems evaluated failed to deliver these enzymes to the appropriate organelles and cells. My group reevaluated these findings, and discovered that these findings were flawed. The delivery failure could be entirely attributed to a subtle, yet highly significant difference between how the target cells behave outside of the body as compared to inside the body. It turned out that the approach was in fact valid, it was the cell based assay that had been used that was flawed. This discovery was striking enough that SENS Research Foundation provided Ichor with funding and a material and technology transfer agreement to reassess the technology, and over $700,000 in directed program investments and grants have been received in the last year or two.

You recently completed a round of funding for the AMD work; what is the plan for the next year or so?

The new funds will allow us to develop a portfolio of enzyme therapy candidates to treat AMD. We will obtain critical data necessary to secure follow-on investment including in vitro studies (cell culture studies to confirm mechanism of action and cytotoxicity) and pivotal proof-of-concept in vivo studies, such as toxicity, PK/PD (how long the enzyme stays in the body and where), and efficacy. We will also be restructuring the company (reincorporating an IP holding company in Delaware, ensuring all contracts are up to date and audited) and ensuring our IP position is on solid footing (licensing in several related patents from existing collaborators, and filing several provisional patents from our intramural work). Collectively, we believe these efforts will position us to obtain series A for investigational new drug (IND) enabling pre-clinical studies.

You’ve been involved in the rejuvenation research community for quite some time now. What is your take on the bigger picture of SENS and the goal of ending aging?

This is a loaded question. What I can say is that the medical establishment has made great progress in the treatment of infectious disease through the development of antibiotics, vaccines, and hygiene programs. However, similar progress has not been realized for the diseases of old age, despite exorbitant expenditures. I have chosen to work in this space because I think a different approach is necessary, and it is here that I believe my companies and I can be the most impactful. I think SENS provides a good framework within which to ask and answer questions.

What do you see as the best approach to getting nascent SENS technologies like this one out of the laboratory and into the clinic?

We need more people who fully understand, in a highly detailed way, what a real translational path looks like. To take on projects like this, being a good scientist is not enough. We need people who can speak business, science, medicine, and legal, and apply these diverse disciplines to a well articulated, focused product or problem. There is no shortage of people who partially understand some of these, but the details are not somewhat important – they are all that matter for success in this space.

Another area is for investors. Some of the projects that come across my desk for review are truly abysmal, yet I have seen projects that are clearly elaborate hoaxes or outright scams (to anyone who has stepped foot in a laboratory) get funded to the tune of hundreds of thousands of dollars or more. While it is perfectly reasonable for high net worth individuals to gamble on moon shots in the anti-aging space (and I am ever grateful for the investors who have taken such a gamble on us) even aggressive development strategies should have some basis in reality. This is especially true as more and more high tech and internet investors move into the space.

If this works stupendously well, what comes next for Ichor Therapeutics?

I really want to get back into stem-cell research, but I basically need a blank check and a strong knowledge of the regulatory path to clinic before I feel comfortable moving into the space. A successful AMD exit would accomplish both of these goals, and position us to pivot to cell-based therapies.

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
***
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.
Public Opposition to Biotech Endangers Your Life and Health – Article by Edward Hudgins

Public Opposition to Biotech Endangers Your Life and Health – Article by Edward Hudgins

The New Renaissance HatEdward Hudgins
******************************

Do you want to be smarter, healthier, and live longer? Remarkably, a new Pew survey found that most Americans answer “No!” if it requires using certain new technologies. This is a wakeup call for scientists, Silicon Valley entrepreneurs, transhumanists, and all of us who value our lives: we must fight for our lives on the battlefield of values.

CRISPRWorries about human enhancement

We all understand how information technology has transformed our world with PCs, smartphones, the Internet, and Google. Nanotech, robotics, artificial intelligence, and, especially, genetic engineering are poised to unleash the next wave of wealth creation and improvements of the human condition.

But a new Pew survey entitled U.S. Public Wary of Biomedical Technologies to “Enhance” Human Abilities found that “Majorities of U.S. adults say they would be ‘very’ or ‘somewhat’ worried about gene editing (68%), brain chips (69%) and synthetic blood (63%),” technologies that in years to come could make us healthier, smarter, and stronger. While some say they “would be both enthusiastic and worried … overall, concern outpaces excitement.” Further, “More say they would not want enhancements of their brains and their blood (66% and 63%, respectively) than say they would want them (32% and 35%).”

Simply a reflection of individuals making decisions about their own lives, as is their right? Not quite. Their concerns about technology are already causing cultural and political pushback from left and right that could derail the advances sought by those of us who want better lives.

The Pew data reveals two ideological sources of opposition to new technologies.

Religion and meddling with nature

brain.chip_.grids_The survey found that 64% of Americans with a high religious commitment say “gene editing giving babies a much reduced disease risk” is “meddling with nature and crosses a line we should not cross.” Are you stunned that anyone could prefer to expose their own babies to debilitating or killer diseases when a prevention is possible?

And 65% with such a commitment have a similar opinion of “brain chip implants for much improved cognitive abilities.” Better to remain ignorant when a way to more knowledge is possible?

Obsession with inequality of abilities

When asked if “gene editing giving babies a much reduced disease risk” is an appropriate use of technology, 54% answered “Yes” if it results in people “always equally healthy as the average person.” But only 42% approved if it results in people “far healthier than any human known to date.” Similarly, 47% approved of synthetic blood if it results in physical improvements in individuals “equal to their own peak ability,” while only 28% approved if it results in improvements “far above that of any human known to date.”

Here we see the ugly side of egalitarianism. Better for everyone to be less healthy than for some to be healthier than others.

synthetic_blood-alamy_SmallThis inequality concern is another aspect of warped values we find in economic discussions. What if everyone enjoys rising levels of prosperity in a free-market system, but some individuals—Steve Jobs? Mark Zuckerberg?—become much wealthier than others through their own productive efforts? It’s win-win! But many would punish and demonize such achievers because they are the “top 1 percent,” even if such treatment means that those achievers produce less and, thus, everyone is less prosperous. Better we’re all poorer but more equal.

A disappearing digital divide

We saw this inequality concern in the 1990s when desktop PCs and the Internet were taking off. Some projected a “digital divide.” There would be more intelligent and advantaged individuals because they could access a universe of information through these technologies. And there would be those with little access who would fall further behind. Of course, what fell was the price of those technologies, which even then were accessible for free at most local libraries and now are in laptops, tablets, and smartphones, and affordable to most low-income individuals. The divide disappeared.

 Computers

There were early adopters prosperous enough to try new information technologies. Similarly, there will be early adopters of biomedical tech, which later will become accessible to all—but only if enough people value it rather than fear it and demand that the government stop it.

The fight for values

In a companion piece to the Pew survey, entitled Human Enhancement: The Scientific and Ethical Dimensions of Striving for Perfection, Pew senior writer David Masci offers a good overview of serious moral issues raised by biotech and other exponential technologies. And those of us who welcome these technologies must fight for the moral values on which they are based.

We truly value our lives, and the happiness and flourishing that we as individuals can get out of them through our own achievements. We must shake others out of their spiritual lethargy so that they too will not let their precious lives waste away.

We must promote the values of reason and science as the means to better technology and as guides for our individual lives. Misguided dogmas, whether religious or political, lead to social and personal stagnation.

We must develop and implement strategies to promote human achievement, including enhancement of our capacities, as a value in our culture through our institutions—schools, media—and our aesthetics—movies, art, music.

We must offer an exciting and compelling vision of a fantastic, nonfiction future, of a world as it can be and should be, especially to young people who thirst for a future that will be worth living.

The values on which this future is based will not sell themselves. We must not only create the technology that will allow us to live healthier, smarter and stronger. We must also create the culture that will encourage and celebrate the creation and use of such technology.

Edward Hudgins is the director of advocacy for The Atlas Society and the editor and author of several books on politics and government policy.

Copyright The Atlas Society. For more information, please visit www.atlassociety.org.

It’s Time to Postpone Your Appointment with the Grim Reaper – Article by Gerrard Jayaratnam

It’s Time to Postpone Your Appointment with the Grim Reaper – Article by Gerrard Jayaratnam

The New Renaissance HatGerrard Jayaratnam
******************************

How long would you like to live for? Is there a limit to how long we can live for? These are not questions you hear often, but do not be surprised if they are repeated more frequently in the future. The reason? Life extension. It is the concept of living well beyond the average lifespan. [1]

Humans are already living longer due to vaccines and improvements in sanitation. [2] The World Health Organization reported that the average life expectancy at birth increased from 48 years in 1955 to 65 years in 1995, and is projected to rise to 73 years by 2025. [3] As medical techniques continue to improve, we are more inclined than ever to pursue life extension. [1] Indeed, from the Epic of Gilgamesh to China’s First Emperor, prolonging life has been an ever-present thought in society. [4, 5] Both individuals failed to escape death, but the idea of life extension ironically lives on. Even so, is it truly possible and what should upcoming doctors and scientists consider if they are to join the most ambitious of quests?

The “Horcruxes” of reality 

In the fictional Harry Potter series, “Horcruxes” were objects where people could hide a fragment of their soul in an attempt to take one step towards immortality. [6] Of course, humans cannot split their souls and hide them in objects, but there are several proposed means by which life extension may be achieved. [1] This is a testimony to the progress within the life extension field, but there remains much room for improvement.

Eat less, live more

Caloric restriction (CR) is one proposed method for life extension. [1] In the CALERIE (Comprehensive Assessment of Long term Effects of Reducing Intake of Energy) trial, 218 non-obese humans were randomised to either a control group or an intervention group. The latter aimed for a 25% reduction from baseline energy intake. At the end of the 2-year study period, the intervention group had significantly greater reductions in circulating levels of TNF-α – an inflammatory marker involved in many age-related diseases. [7] Dr Alexander Miras, winner of the 2014 Nutrition Society Cuthbertson Medal for his research on bariatric surgery, acknowledges that the study was a “good first step,” but argues that “the evidence in humans is lacking.” “A definitive RCT (randomised controlled trial),” Dr Miras continues, “would be very hard, if not impossible.” He also spots a glaring consequence of CR. “My personal approach is to avoid caloric restriction as this leads to hunger which is an unpleasant feeling. I would rather live a shorter life, but enjoy my food.”

Manipulating telomerase

One alternative is modulating telomerase activity – as attempted with the anti-ageing TA-65MD® supplement. [8] Telomeres protect the ends of chromosomes [9]; they resemble the aglets on the ends of shoelaces. Just as shoelaces would unravel without the aglet, chromosomes would lose vital DNA sequences in the absence of telomeres. [9] Our cells divide over time, causing telomeres to shorten. Once the telomere becomes too short, cell division ceases, and short telomeres correlate with cellular ageing. [10] Telomerase is an enzyme that can oppose telomere shortening [10] – it was what Hamlet was to King Claudius; what exercise is to obesity; and what junior doctors, in England, will be to Jeremy Hunt.

Reactivating telomerase in telomerase-deficient mice reversed both neurodegeneration and degeneration of other organs. [11] This proved the concept that boosting telomerase activity could have anti-ageing effects, but there is little proof that this occurs in humans. While the mice were telomerase-deficient, humans normally have some telomerase activity. It is like giving food to someone who has been fasting for hours and to someone who has just eaten a three-course meal – the starved individual would unquestionably benefit more. A 12-month long RCT, involving 117 relatively healthy individuals (age range: 53-87), found that low-dose TA-65 significantly increased telomere length when compared to placebo. High-dose TA-65, however, failed to do so. [12]

Dancing with the devil

What is more worrying than treatments that may be ineffective? Side effects. Telomerase is a double-edged sword and by reducing telomere attrition, it can promote unlimited cell division and cancer. [9] Elizabeth Blackburn, co-winner of the 2009 Nobel Prize in Physiology or Medicine for her role in the discovery of telomerase, has doubts about exploiting the enzyme. Speaking to TIME magazine, she said, “Cancers love telomerase, and a number of cancers up-regulate it like crazy. . . . My feeling would be that if I take anything that would push my telomerase up, I’m playing with fire.” [13]

A cauldron of rewards

CR and boosting telomerase activity are just a small sample of life extending techniques, yet there is the notion that such techniques will be intertwined with risks. However, risks are always weighed against rewards, and Gennady Stolyarov, editor-in-chief of The Rational Argumentator and Chief Executive of the Nevada Transhumanist Party, believes life extension would bring “immense and multifaceted” rewards. “The greatest benefit is the continued existence of the individual who remains alive. Each individual has incalculable moral value and is a universe of ideas, experiences, emotions, and memories. When a person dies, that entire universe is extinguished . . . This is the greatest possible loss, and should be averted if at all possible.” Stolyarov also envisages “major savings to healthcare systems” and that “the achievement of significant life extension would inspire many intelligent people to try to solve other age-old problems.”

Former chairman of the President’s Council on Bioethics, Leon Kass, disagrees with this view and argues that mortality is necessary for “treasuring and appreciating all that life brings.” [14] Hence, increased longevity could lead to an overall reduction in productivity over one’s lifetime. Perhaps Kass is correct, but the array of potential benefits makes it seem unwise to prematurely dismiss life extension. In fact, a survey, which examined the opinions of 605 Australians on life extension, highlighted further benefits – 23% of participants said they could “spend more time with family” and 4% cited the opportunity to experience future societies. [15]

Learning from our mistakes

Conversely, life extension may result in people enduring poor health for longer periods. 28% of participants in the Australian survey highlighted this concern. [15] Current trends in life expectancy reinforce their fears. Professor Janet Lord, director of the Institute of Inflammation and Ageing at the University of Birmingham, explains, “Currently, in most countries in the developed world, life expectancy is increasing at approximately 2 years per decade, but healthspan (the years spent in good health) is only increasing at 1.7 years. This has major consequences . . . as more of later life is spent in poor health.” This is a consequence of treating “killer diseases” – according to Dr Felipe Sierra, director of the Division of Aging Biology at the National Institute on Aging. “The current model in biomedicine,” says Dr Sierra, “is to treat one disease at a time. Let’s imagine you have arthritis; cancer; and are starting to develop Alzheimer’s disease. So what do we do? We treat you for cancer. You now live longer with Alzheimer’s disease and arthritis.” A better approach is clear to Dr Sierra who stresses the importance of compression of morbidity – “the goal is to live longer with less time spent being sick.”

Learning from our successes

Even with Dr Sierra’s approach, individual boredom and social implications, including overpopulation, would still be problems.[16] According to Stolyarov, the boredom argument does not hold up when facing “human creativity and discovery.” He believes humans could never truly be bored as “the number of possible pursuits increases far faster than the ability of any individual to pursue.”

In his novel Death is Wrong, Stolyarov explained that the idea that society could not cope with a rapidly expanding population was historically inaccurate. The current population “is the highest it has ever been, and most people live far longer, healthier, prosperous lives than their ancestors did when the Earth’s population was hundreds of times smaller.” [16] If it has been achieved in the past, who is to say our own society – one far more advanced than any before it – cannot adapt?

The verdict

Life extension research is quietly progressing, and there is a good chance that it will eventually come to fruition. Although there are doubts about current techniques, Dr Sierra draws attention to novel interventions, such as rapamycin, which “delay ageing in mice.” He concludes that the next challenge is to “develop measures than can predict whether an intervention works in a short-term assay.” Such measures would provide the scaffolding for future clinical trials that test life extension techniques.

Given what may be gained, it is no surprise that artificially prolonging life is exciting some in the same way the Tree of Knowledge tempted Eve. The impact on society? Impossible to predict. It would undoubtedly be a big risk, but perhaps in this complex and uncertain scenario, we ought to remember the words of the poet Thomas Stearns Eliot: “Only those who will risk going too far can possibly find out how far one can go.” [17]

Gerrard Jayaratnam is a student of Biomedical Science at Imperial College London.

References

  1. Stambler I. A History of Life-Extensionism in the Twentieth Century. Ramat Gan: CreateSpace Independent Publishing Platform; 2014.
  2. National Institute on Aging. Living Longer. 2011. https://www.nia.nih.gov/research/publication/global-health-and-aging/living-longer.
  3. World Health Organization. 50 Facts: Global Health situation and trends 1955-2025. 2013. http://www.who.int/whr/1998/media_centre/50facts/en/.
  4. Encyclopaedia Britannica. Epic of Gilgamesh. 2016. http://www.britannica.com/topic/Epic-of-Gilgamesh.
  5. Lloyd DF. The Man Who Would Cheat Death and Rule the Universe. Vision. 2008. http://www.vision.org/visionmedia/history-shi-huang-emperor-china/5818.aspx.
  6. Rowling JK. Harry Potter and the Half-Blood Prince. London: Bloomsbury Publishing; 2005.
  7. Ravussin E, Redman LM, Rochon J, et al. A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity. J Gerontol A Biol Sci Med Sci 2015;70:1097-1104.
  8. A. Sciences. What is TA-65®? (n.d.) [Accessed 3rd April 2016]. https://www.tasciences.com/what-is-ta-65/.
  9. De Jesus BB, Blasco MA. Telomerase at the intersection of cancer and aging. Trends Genet 2013;29:513-520.
  10. A. Sciences. Telomeres and Cellular Aging. (n.d.) [Accessed 3rd April 2016]. https://www.tasciences.com/telomeres-and-cellular-aging/.
  11. Jaskelioff M, Muller FL, Paik JH, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase deficient mice. Nature 2011;469:102-106.
  12. Salvador L, Singaravelu G, Harley CB, et al. A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study. Rejuvenation Res 2016; ahead of print. doi:10.1089/rej.2015.1793.
  13. Kluger J. The antiaging power of a positive attitude. TIME. 2015.
  14. Than K. The Psychological Strain of Living Forever. Live Science. 2006. http://www.livescience.com/10469-psychological-strain-living.html.
  15. Partridge B, Lucke J, Bartlett H, et al. Ethical, social, and personal implications of extended human lifespan identified by members of the public. Rejuvenation Res 2009;12:351-357.
  16. Stolyarov II G. Death is Wrong. 2nd ed. Carson City, Nevada: Rational Argumentator Press; 2013.
  17. The Huffington Post. 11 Beautiful T.S. Eliot Quotes. 2013. http://www.huffingtonpost.com/2013/09/26/ts-eliot-quotes_n_3996010.html.
G. Stolyarov II Interviews Demian Zivkovic Regarding the D.N.A. – Gene Therapies Congress

G. Stolyarov II Interviews Demian Zivkovic Regarding the D.N.A. – Gene Therapies Congress

The New Renaissance Hat
G. Stolyarov II and Demian Zivkovic
******************************

Mr. Stolyarov invited Demian Zivkovic, President of the Institute of Exponential Sciences (IES), to discuss the forthcoming Designing New Advances (D.N.A.) Gene Therapies Congress in Utrecht, The Netherlands.

The interview took place on Sunday, June 19, 2016, at 11 a.m. US Pacific Time. Watch the recording here.

The D.N.A. Congress is scheduled to occur on July 9, 2016, and will feature speakers such as Oliver Medvedik, Aubrey de Grey, Elizabeth Parrish, Keith Comito, and Tatjana Kochetkova. This event receives the strong endorsement of both The Rational Argumentator and the Nevada Transhumanist Party.

Read the announcement of the D. N. A. Congress here.

Contribute to the fundraiser for the D. N. A. Congress on Indiegogo  and Generosity.

DNA_Interview_CoverDemian Zivkovic is the president of the Institute of Exponential Sciences  (Facebook  / Meetup) – an international transhumanist think tank / education institute comprised of a group of transhumanism-oriented scientists, professionals, students, journalists, and entrepreneurs interested in the interdisciplinary approach to advancing exponential technologies and promoting techno-positive thought. He is also an entrepreneur and student of artificial intelligence and innovation sciences and management at the University of Utrecht.

Demian and the IES have been involved in several endeavors, such as organizing lectures on exponential sciences, interviewing experts such as Aubrey de Grey, joining several of Mr. Stolyarov’s futurism panels, and spreading Death is Wrong – Mr. Stolyarov’s illustrated children’s book on indefinite life extension – in The Netherlands.

Demian Zivkovic is a strong proponent of healthy life extension and cognitive augmentation. His interests include hyperreality, morphological freedom advocacy, postgenderism, and hypermodernism. He is currently working on his ambition of raising enough capital to make a real difference in life extension and transhumanist thought.

D.N.A. Congress Announcement by the Institute of Exponential Sciences

D.N.A. Congress Announcement by the Institute of Exponential Sciences

The New Renaissance HatInstitute of Exponential Sciences
******************************
 

Editor’s Note: The forthcoming D.N.A. Congress in Utrecht, The Netherlands, hosted by the Institute of Exponential Sciences, devoted to discussions of gene therapies, receives the strong endorsement of both The Rational Argumentator and the Nevada Transhumanist Party. The D.N.A. Congress offers a promising venue to discuss the potential for gene therapies to cure diseases, lengthen lifespans, and improve quality of life for millions of people in the coming years and decades.

~ Gennady Stolyarov II, Editor-in-Chief, The Rational Argumentator, June 5, 2016

D.N.A CONGRESS PRESS RELEASE:

The Institute of Exponential Sciences (IES) has a large announcement to make. We are organising D.N.A – The largest European congress on human gene therapies, featuring speakers such as Aubrey de Grey, Liz Parrish, Oliver Medvedik and others.

Our event has been endorsed by LEAF, Heales VZW, BioViva, SENS Research Foundation, Singularity Network, People Unlimited, The Rational Argumentator, and many others. The event will be covered by national media and will be broadcasted online.

To make this vision a reality, we need your support. Share this message and donate today. Thank you!

IES needs your support to help make this vision a reality. Click here to donate to our crowdfunding campaign.

D.N.A – Designing New Advances: The second large Institute of Exponential Sciences event is coming to Utrecht

 

DNADemian Zivkovic

Utrecht – After a successful event last year in May, the grand congress is ready for a second edition. With a new name, we hope to make exponential sciences more approachable to the general public and bring people in the field closer together. The Institute of Exponential Sciences congress 2016 will be held at RASA podium on the 9th of July. The main theme of the event is gene therapies and cutting-edge applications of such therapies, such as health extension and interventions against human aging. To guarantee a great event, we have invited some of the biggest names in the field. Our guest speakers will be as follows:

Opening the event will be Oliver Medvedik, Ph.D, director of scientific programs at Genspace. Dr. Medvedik has earned his Ph.D at Harvard Medical school in the biomedical and biological sciences program. Since graduating from Harvard, he has worked as a biotechnology consultant, taught molecular biology to numerous undergraduates at Harvard, and mentored two of Harvard’s teams for the international genetically engineered machines competition (IGEM) held annually at M.I.T.

Our second speaker is Aubrey David Nicholas Jasper de Grey, Ph.D, an English author, Chief Science Officer of the SENS Research Foundation, and editor-in-chief of the academic journal Rejuvenation Research. Aubrey de Grey is well known for his focus on regenerative medicine and views on human aging. He will take the stage talking about the applications of current and upcoming technologies and studies which hold the potential to greatly extend our healthy lifespan.

Our third speaker is Tatjana Kochetkova, Ph.D, who is a fellow of the Institute of Exponential Sciences and a bioethicist. Dr. Kochetkova will follow up discussing the ethical and philosophical side of the technology and will address questions of what exponential technologies in biotech mean for society.

Our fourth speaker is Elizabeth Parrish, a fellow of the Institute of Exponential Sciences and the Founder and CEO of BioViva Sciences Inc, a Delaware corporation based in Seattle, WA, with labs and participating clinics in South/Central America where the majority of practical work is carried out. BioViva has been noted for being the first corporation in the world to treat a patient with gene therapy to reverse aging. The woman who wants to genetically engineer you will cover the basics of BioViva’s approach and vision for the the future, as well as the potential that gene therapies hold for radically improving our health and lives in the future.

Our fifth speaker will be Keith Comito, who is the founder and president of the Life Extension Advocacy Foundation (LEAF), a 501(c)(3) non-profit organization and a partner of the Institute of Exponential Sciences. Through LEAF, he operates the crowdfunding platform Lifespan.io, which supports biomedical research aimed at extending healthy human lifespan. He also serves as policy coordinator for the Global Healthspan Policy Institute, which facilitates relationships between researchers and government to advance initiatives in support of healthy life extension.

About Institute of Exponential Sciences

The Institute of Exponential Sciences is an international innovation-oriented think tank, outreach organisation, and networking platform based in the Netherlands, in the city of Utrecht. Its main activities include organising lectures and conferences, providing quality consultancy on innovation and exponential technologies, and collaborating with student organisations and universities in educating the public on the importance of exponential technologies.

It was founded by members of its predecessor, the Arma’thwynn society, which was a student group of like-minded young academics in the Netherlands. After organising events and attracting a very diverse and professional team of entrepreneurs, academics, and journalists, the society decided to move past student politics and make the move towards professionalism.

The Institute of Exponential Sciences is the result of that decision. After organising successful events (the largest of which was their symposium in April, 2015), the Institute of Exponential Sciences formalised its mission and reached out towards a process of international collaboration with other entities which share a techno-positive vision. The institute strives towards excellence in providing the best information and resources related to the issues relevant in the rapidly advancing technological society we live in.

The IES approach is focused on providing interdisciplinary education in the fields of exponential technologies such as artificial intelligence, bio-informatics, gene therapies, 3D-printing, augmented reality, and neural interfacing. We also provide a networking platform which allows entrepreneurs, scientists, journalists, and students to get in touch with others with similar ideas so that they may create the technologies of tomorrow. The IES strives not only to improve the speed of development of these technologies, but also to show the public the amazing possibilities technology provides for society.

IES and the IES logo are either registered trademarks or trademarks of IES Foundation in the Netherlands and/or other countries. All other products and/or services referenced are trademarks of their respective entities.

A Transhumanist Manifesto for Calgary and Beyond – Article by Reed Nelson

A Transhumanist Manifesto for Calgary and Beyond – Article by Reed Nelson

Reed Nelson
******************************
What is Transhumanism?

Transhumanism is the idea, philosophy, movement, what have you, that human beings both can and should be enhanced by the use of technology. So while some people use glasses, cars, phones computers, airplanes, and so forth, well, we Transhumanists want to go further.

A lot further.

We want robotic hearts, we want to stay young, we want to be stronger, faster, smarter, and more loving than we are now.

And we don’t people to feel depression, or rage, or extreme loneliness, or to experience cancer, AIDS, or disability of any sort.

We want everyone to feel and function well, all of the time, and we want to grow as never before.

Now consider this.

For the entirety of our species we have only been changing the external – where we live, what clothes we wear, what religions we devote ourselves to and so forth.

And now, I and many others believe that it is time to change the inside.

It is time to evolve.

On Rational Devotion

It seems to me that within Christianity, as well as many other religions, there is the idea that one must devote to God, and God will respond – that is to say, God will heal you in his time.

His time? Does that mean, not even in this life, and yet still you are asked to devote?

(Oh, and why does he heal say, loneliness but not an amputee?)

If God is real, then at minimum, he should meet us halfway, and for each prayer, a little healing, and for each verse read, a little healing.

But of course it doesn’t work that way, and the believer is told to keep going and just, well, believe. That to me sounds like mental slavery.

And I will have none of it.

Technology heals. Nature heals. Animals heal. People heal each other.

And technology has the potential to be, and often already is, the greatest healer of all.

Why devote to anything else then?

P. S. In the movie Forrest Gump, what heals the legs of Lt. Dan? Oh right, technology.

Please, brothers and sisters, let us now turn away from the empty promises of holy books, and instead let us support Transhumanism, for it shall lead us to real healing.

So now we come to arguably our crystalline truth – if there is a biological problem, there is a biological solution.

Zoltan Istvan for American President 2016.

Spread the Good News.

Reed Nelson is the founder of The Transhumanist Party of Calgary in Alberta, Canada. See the Facebook page of The Transhumanist Party of Calgary here.

Happy Future Day! – Article by Edward Hudgins

Happy Future Day! – Article by Edward Hudgins

The New Renaissance HatEdward Hudgins
******************************

Stand up for optimism about the future today!

Transhumanism Australia, a non-profit that promotes education in science and technology, has marked March 1 as “Future Day.” It wants this day celebrated worldwide as a time “to consider the future of humanity.” If all of us made a habit of celebrating our potential, it could transform a global culture mired in pessimism and malaise. It would help build an optimistic world that is confident about what humans can accomplish if we put our minds and imaginations to it.

The Future is Bright

The information and communications technology that helps define and shape our world was, 40 years ago, a vision of the future brought into present reality by visionaries like Steve Jobs and Bill Gates. The exponential growth of the power of semiconductors allowed entrepreneurs to create one new industry and cutting-edge good product and service after another.

futureToday, we are at exponential takeoff points in biotech, nanotech, and artificial intelligence. For example, the cost of sequencing a human genome was $100 million in 2001, $10 million in 2007, but it costs only a few thousand dollars today. Steve Jobs created the first Apple computers in his garage. Biohackers similarly housed could transform our lives in the future in ways that still seem to most folks like science fiction; indeed, the prospect of “curing death” is no longer a delusion of madmen but the well-funded research projects in the laboratories of the present.

For a prosperous present and promising future a society needs physical infrastructure—roads, power, communications. It needs a legal infrastructure—laws and political structures that protect the liberty of individuals so they can act freely and flourish in civil society. And it requires moral infrastructure, a culture that promotes the values of reason and individual productive achievement.

Future “Future Days”

We should congratulate our brothers “Down Under” for conceiving of Future Day. They have celebrated it in Sydney with a conference on the science that will produce a bright tomorrow. We in America and folks around the world should build on this idea. Today it’s a neat idea: next year, we could start a powerful tradition, a global Future or Human Achievement Day, promoting the bright future that could be.

Were such a day marked in every school and every media outlet, it could to raise achiever consciousness. It could celebrate achievement in the culture—who invented everything that makes up our world today, and how? It could promote achievement as a central value in the life of each individual, whether the individual is nurturing a child to maturity or a business to profitability, writing a song, poem, business plan or dissertation, laying the bricks to a building or designing it, or arranging for its financing.

Such a day would help create the moral infrastructure necessary for a prosperous, fantastic, non-fiction future, a world as it can be and should be, a world created by humans for humans—or even transhumans!

Dr. Edward Hudgins directs advocacy and is a senior scholar for The Atlas Society, the center for Objectivism in Washington, D.C.

Copyright The Atlas Society. For more information, please visit www.atlassociety.org.

G. Stolyarov II Interviews Adam Alonzi Regarding Emerging Biotech Research

G. Stolyarov II Interviews Adam Alonzi Regarding Emerging Biotech Research

The New Renaissance Hat
G. Stolyarov II and Adam Alonzi
August 28, 2015
******************************

On August 23, 2015, Mr. Stolyarov invited Adam Alonzi to share the insights he was able to glean from many recent discussions with biotechnology entrepreneurs and researchers. Mr. Alonzi was able to subsequently edit some of his remarks to remedy the technical issues with audio quality during the broadcast. His edited version appears below.

See the original interview recording:

Adam Alonzi is the author of Praying for Death and A Plank in Reason. He is also a futurist, inventor, DIY enthusiast, biotechnologist, programmer, molecular gastronomist, consummate dilletante and columnist at The Indian Economist. Read his blog here. Listen to his podcasts at http://adamalonzi.libsyn.com.

Adam Alonzi’s Interviews
Elizabeth Parrish – BioViva
Alex Zhavoroknov – InSilico Medicine
Maria Konovalenko – Science for Life Extension Foundation and Longevity Cookbook
Luis Arana – Robots Without Borders

Google, Entrepreneurs, and Living 500 Years – Article by Edward Hudgins

Google, Entrepreneurs, and Living 500 Years – Article by Edward Hudgins

The New Renaissance Hat
Edward Hudgins
March 29, 2015
******************************

“Is it possible to live to be 500?”

“Yes,” answers Bill Maris of Google, without qualifications.

A Bloomberg Markets piece on “Google Ventures and the Search for Immortality” documents how the billions of dollars Maris invests each year is transforming life itself. But the piece also makes clear that the most valuable asset he possesses —and that, in others, makes those billions work—is entrepreneurship.

Google’s Bio-Frontiers

Maris, who heads a venture capital fund set up by Google, studied neuroscience in college. So perhaps it is no surprise that he has invested over one-third of the fund’s billions in health and life sciences. Maris has been influenced by futurist and serial inventor Ray Kurzweil who predicts that by 2045 humans and machines will merge, radically transforming and extending human life, perhaps indefinitely. Google has hired Kurzweil to carry on his work towards what he calls this “singularity.”

Maris was instrumental in creating Calico, a Google company that seeks nothing less than to cure aging, that is, to defeat death itself.  This and other companies in which Maris directs funds have specific projects to bring about this goal, from genetic research to analyzing cancer data.

Maris observes that “There are a lot of billionaires in Silicon Valley, but in the end, we are all heading for the same place. If given the choice between making a lot of money or finding a way to live longer, what do you choose?”

Google Ventures does not restrict its investments to life sciences. For example, it helped with the Uber car service and has put money into data management and home automation tech companies.

“Entrepreneuring” tomorrow

Perhaps the most important take-away from the Bloomberg article is the “why” behind Maris’s efforts. The piece states that “A company with $66 billion in annual revenue isn’t doing this for the money. What Google needs is entrepreneurs.” And that is what Maris and Google Ventures are looking for.

They seek innovators with new, transformative and, ultimately, profitable ideas and visions. Most important, they seek those who have the strategies and the individual qualities that will allow them to build their companies and make real their visions.

Entrepreneurial life

But entrepreneurship is not just a formula for successful start-ups. It is a concept that is crucial for the kind of future that Google and Maris want to bring about, beyond the crucial projects of any given entrepreneur.

Entrepreneurs love their work. They aim at productive achievement. They are individualists who act on the judgments of their own minds. And they take full responsibility for all aspects of their enterprises.

On this model, all individuals should treat their own lives as their own entrepreneurial opportunities. They should love their lives. They should aim at happiness and flourishing—their big profit!—through productive achievement. They should act on the judgments of their own minds. And they should take full responsibility for every aspect of their lives.

And this entrepreneurial morality must define the culture of America and the world if the future is to be the bright one at which Google and Maris aim. An enterprise worthy of a Google investment would seek to promote this morality throughout the culture. It would seek strategies to replace cynicism and a sense of personal impotence and social decline with optimism and a recognition of personal efficacy and the possibility of social progress.

So let’s be inspired by Google’s efforts to change the world, and let’s help promote the entrepreneurial morality that is necessary for bringing it about.

Dr. Edward Hudgins directs advocacy and is a senior scholar for The Atlas Society, the center for Objectivism in Washington, D.C.

Copyright, The Atlas Society. For more information, please visit www.atlassociety.org.